Atrial fibrillation: Prevalence and management in an acute general medical unit

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 1, 1999, Pages 51-58

  Stewart, F M ^a   Singh, Y ^a   Persson, S ^a   Gamble, G D ^b   Braatvedt, Geoffrey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticoagulation; Atrial fibrillation; Heart rate control; Management

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PREVALENCE; STROKE; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 0032979223     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb01588.x     Document Type: Article

References (28)

1. 1. Wolf PA, Abbott RD, Kanel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
2. 2. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 1992; 117: 141-50.
3. 3. Juul-Möller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus Quinidine for the maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation. Circulation 1990; 82: 1932-9.
4. 4. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral Propafenane therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 12: 1005-11.
5. 5. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991; 68: 335-41.
6. 6. Cowan JC. Antiarrhythmic drugs in the management of atrial fibrillation. Br Heart J 1993; 70: 304-6.
7. 7. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of Quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
8. 8. Nattel S, Hadjis T, Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs 1994; 48: 345-71.
9. 9. Prytowsky EN, Benson DW, Fuster V et al. Management of patients with atrial fibrillation. A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-77.
10. 10. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
11. 11. SAS Institute, SAS STAT Guide for Personal Computers; SAS Institute, Cary NC, 1995.
12. 12. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12.
13. 13. Lip GYH, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994; 71: 92-5.
14. 14. Nordyke RA, Gilbert FI, Harada ASM. Grave's disease: influence of age on clinical findings. Arch Intern Med 1988; 148: 626-31.
15. 15. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE, Gallagher JJ, German LD. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563-70.
16. 16. Falk RH, Leavitt JI. Digoxin for atrial fibrillation: A drug whose time has gone? Ann Intern Med 1991; 114: 573-5.
17. 17. Pollack A, Falk RH. Pacemaker therapy in patients with atrial fibrillation. Am Heart J 1993; 125: 824-30.
18. 18. Mancini GBJ, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker and long-term success. Am Heart J 1982; 104: 617-21.
19. 19. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-39.
20. 20. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
21. 21. Peterson P, Boys G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; i: 175-9.
22. 22. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
23. 23. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL et al., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
24. 24. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CAFA Study Co-investigators. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55.
25. 25. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
26. 26. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-8.
27. 27. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
28. 28. Munschauer FE, Priore RL, Hens M, Castilone A. Thromboembolism prophylaxis in chronic atrial fibrillation. Practice patterns in community and tertiary-care hospitals. Stroke 1997; 28: 72-6.